Navigation Links
Revolutionary Therapy: Needle-Free Technology for the Treatment Of Blinding Eye Disease
Date:6/19/2008

ople with the "wet" form of the disease, which currently is the only treatable form of AMD and requires the injection of drugs directly into the eye. The market is conservatively estimated at over $200 million annually in the US alone.

Other retinal damage caused by Diabetes related eye disease can also benefit from the device and available treatments.

Media Contacts

Susan Fitzpatrick

susan@datelinemedia.com

In San Diego Cell: 650 279 7771

Tania Ewing

In Australia Cell: 0408378422

taniaewing@healthinbox.com

Sydney office: +1 612 9006 1614

US office: 650 798 5238


'/>"/>
SOURCE Seagull Technology Pty Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Edge Health Solutions Releases edgeDMS(TM) 2.0 and edgeMD 2.0(TM), Revolutionary All-in-One Practice Management Software with FDA-Approved Advanced Visualization
2. New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
3. Accuri Cytometers Announces Commercial Launch of Revolutionary Accuri C6 Flow Cytometer(TM) System
4. Revolutionary New Technique Uses Onyx to Fill Hard-To-Treat Aneurysms
5. ReBuilder Medical Technologies, Inc. Announces Revolutionary Electronic Zapper Said to Destroy Molluscum Contagiosum Pathogen
6. First Responders Acquire Revolutionary MyClyns(TM) Protective Spray
7. ILC Dover Launches Revolutionary ArmorFlex (R) Pharmaceutical Product Contact Film
8. 10th Anniversary of Revolutionary Teaching Approach that Offers the Severely Disabled the Gift of Self-Expression - Through Painting
9. Precedent Launches Revolutionary Individual Health Insurance Plans in Texas
10. Revolutionary HD Surgical Footage from North Shore-LIJ Surgeon to be Broadcast for the First Time on ABCs 20/20, National Geographic Channel
11. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Express Scripts Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of WellPoint's NextRx Subsidiaries 2Health News:CVS/pharmacy Introduces New Coupon Center on CVS.com 2Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 2Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 3Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 4Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 5Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 6Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 2Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 3Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 4Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 5Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 6Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 7Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 8Health News:iUniverse Hosts Canadian Storytellers, Cystic Fibrosis Awareness Advocate for BookExpo America 2009 Book Signings 2Health News:New Website, ElasticBandageStore.com, Offers Elastic Bandages at Wholesale Prices 2
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Marc Russo Named Vice President of Senior Markets at Blue Shield of California 57132 1Marc Russo Named Vice President of Senior Markets at Blue Shield of California 57132 2MUSC Researchers Concerned About Online Drug Availability 57128 1MUSC Researchers Concerned About Online Drug Availability 57128 2HealthSouth Declares Dividend on 6 5 25 Series A Convertible Perpetual Preferred Stock 57123 1